Statute Details
- Title: Medicines (Medical Advertisements) Regulations
- Act Code: MA1975-RG2
- Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Chapter 176), Sections 52 and 74
- Current status: Current version as at 27 Mar 2026
- Regulatory focus: Permits, exceptions, and compliance controls for medical advertisements and sales promotions of medicinal products
- Key provisions (from extract): Regulation 2 (definitions); Regulation 3 (permit requirement); Regulation 6 (terms and conditions); Regulation 7 (refusal/suspension/revocation and appeal); Regulation 8 (printer/publisher duty); Regulation 10–11 (exceptions); Regulation 12 (permit number display); Regulation 13 (alterations/amendments); Regulation 13A (transfer); Regulation 14 (fees); Regulation 15 (penalty)
- Schedule: Fees
- Notable amendments (high level): Multiple amendments including S 548/2016 (effective 1 Nov 2016), S 96/2019 (effective 2 Apr 2019), S 462/2022 (effective 1 Jul 2022), and S 493/2024 (effective 1 Jul 2024)
What Is This Legislation About?
The Medicines (Medical Advertisements) Regulations (“the Regulations”) regulate how medicinal products may be advertised in Singapore. In practical terms, the Regulations create a licensing-and-permit regime: before a person issues or publishes a “medical advertisement” (or conducts a “sales promotion”), the person must obtain a permit from the licensing authority, unless a specific statutory exception applies.
The Regulations are designed to manage public health and consumer protection risks associated with pharmaceutical marketing. Medical advertising can influence prescribing and consumer behaviour, and it may also create compliance risks if claims, warnings, or promotional formats are misleading or insufficient. By requiring prior permission, controlling alterations, and imposing penalties for non-compliance, the Regulations aim to ensure that medicinal product promotion is appropriately reviewed and monitored.
Although the Regulations are framed around “advertisements”, they also regulate the operational steps around advertising—such as the duties of printers and publishers, the display of permit numbers, and restrictions on altering content after a permit is granted. This makes the Regulations relevant not only to brand owners and marketing teams, but also to agencies, publishers, printers, and other intermediaries involved in dissemination.
What Are the Key Provisions?
1. Permit requirement for medical advertisements and sales promotions (Regulation 3). The core rule is straightforward: except as provided in the Regulations, no person shall (a) issue or cause to be issued any medical advertisement, or (b) conduct any sales promotion, without first obtaining a permit from the licensing authority. This is a “no permit, no publication” approach. For practitioners, the key compliance question is whether the planned communication falls within the definition of “medical advertisement” and whether it constitutes a “sales promotion”.
2. Definitions and scope (Regulation 2). The Regulations define “medical advertisement” as any advertisement of a medicinal product, but exclude certain advertisements referenced in the Medicines Act (section 51(1)(a) or (b) or (2)). They also define “sales promotion” broadly to include sales campaigns (including door-to-door sales and price discounts), exhibitions, competitions, and other activities meant to introduce, publicise, raise the profile, public awareness, or visibility of the medicinal product. This breadth means that promotional activities that might be viewed as “marketing” rather than “advertising” can still fall within the regulatory regime.
3. Application, validity, and conditions (Regulations 4–6). An application for a permit (or renewal) must be in the form required by the licensing authority. Permits are generally valid for one year from the date granted unless sooner revoked (Regulation 5). A permit may be granted subject to terms and conditions the licensing authority considers fit (Regulation 6). In practice, the permit conditions may govern content, format, dissemination channels, disclaimers, or other compliance requirements. For counsel, it is essential to treat the permit as a binding instrument: marketing teams should not assume that approval is “content-only” or that conditions are optional.
4. Refusal, suspension, revocation, and appeal (Regulation 7). The licensing authority may refuse to grant a permit, or suspend or revoke an existing permit, without assigning any reason. Any person aggrieved may appeal to the Minister, whose decision is final. This structure has two implications: (i) applicants should expect limited procedural transparency at the initial stage; and (ii) if a permit is refused or revoked, the appeal route is the principal remedy, and counsel should prepare the appeal strategy accordingly.
5. Duties of printers and publishers (Regulation 8). Regulation 8 imposes a compliance duty on intermediaries: no person shall print or publish (or cause to be printed or published) any medical advertisement that is not a sales promotion unless the printer/publisher has ascertained that a permit has been granted for that advertisement. This is a significant operational safeguard. It means that publishers and printing houses cannot treat permit status as purely the responsibility of the advertiser; they must implement verification steps.
6. Exceptions for targeted and non-public communications (Regulations 10–11). The Regulations do not apply to certain categories. Regulation 10 provides an exception where the medical advertisement is directed exclusively at persons who may lawfully sell or supply medicinal products in the course of their trade, business or profession, and is not accessible to the general public. Regulation 11 excludes (a) a “reference advertisement” and (b) a “trade advertisement”, and also excludes medical advertisements issued or published by a public authority or by a person authorised by the Minister.
For practitioners, these exceptions are often where compliance decisions are made. The terms “directed exclusively” and “not accessible to the general public” require careful factual assessment (e.g., whether a mailing list is truly restricted, whether online access is effectively blocked, and whether third parties can view the content). Similarly, the definitions of “reference advertisement” and “trade advertisement” contain specific structural and content limitations (for example, “trade advertisement” must be in a catalogue/price list or similar document for wholesale supply and must not contain recommendations relating to use other than as part of the medicinal product name or therapeutic classification headings).
7. Permit number display (Regulation 12). A person who issues or publishes any medical advertisement (including conducting a sales promotion) must ensure that the permit number is displayed on, or on material accompanying, the advertisement in accordance with terms and conditions specified in the permit. This requirement supports traceability and enforcement. Practically, it requires coordination between regulatory affairs and creative/production teams to ensure the permit number is correctly placed and formatted.
8. Alterations after permit approval (Regulation 13). A person must not alter or amend the contents of a medical advertisement for which a permit has been granted unless (a) an application is made in the form required to amend the permit to reflect the alteration/amendment, and (b) the application is approved by the licensing authority. This prevents “scope creep” where marketing teams make post-approval changes (even seemingly minor ones) without regulatory sign-off. Counsel should advise that changes to claims, indications, dosage references, imagery, or even certain wording may constitute an impermissible alteration requiring an amendment permit.
9. Transfer of permits (Regulation 13A). A permit cannot be transferred unless the person makes an application (in the required form) to transfer the permit to another person and the application is approved by the licensing authority. This matters in corporate transactions, brand transfers, outsourcing arrangements, or changes in marketing responsibility. It also affects how agencies and distributors structure their contractual roles.
10. Fees and no refunds (Regulation 14 and Schedule). Fees are payable for applications for permits, permits/renewals, applications to amend permits, and applications to transfer permits, as specified in the Schedule. No refund is made for any fee paid. For budgeting and procurement, counsel should ensure that fee assumptions are aligned with the no-refund rule.
11. Penalty for non-compliance (Regulation 15). Any person who contravenes or fails to comply with Regulations 3, 8, 12, or 13 commits an offence. On conviction, liability includes a fine not exceeding $5,000, imprisonment not exceeding 12 months, or both. This is a meaningful enforcement lever. While the maximum fine may appear modest relative to some regulatory regimes, the availability of imprisonment underscores the seriousness of permit-related compliance breaches.
How Is This Legislation Structured?
The Regulations are structured as a short set of numbered regulations followed by a Schedule. The main body contains:
Regulations 1–2: Citation and definitions.
Regulations 3–7: The permit requirement, application process, validity period, conditions, and the licensing authority’s powers to refuse/suspend/revoke, including appeal to the Minister.
Regulations 8–13A: Operational compliance duties (printer/publisher duty), exceptions, permit number display, restrictions on altering content, and rules on permit transfer.
Regulations 14–15: Fees (with the Schedule specifying amounts) and penalties.
The Schedule sets out the fees payable for the various regulatory actions.
Who Does This Legislation Apply To?
The Regulations apply to “any person” who issues or publishes medical advertisements or conducts sales promotions, and also to printers and publishers who print or publish medical advertisements. This includes manufacturers, importers, distributors, marketing agencies, publishers, and printing houses—any party involved in the creation and dissemination of promotional materials.
In addition, the exceptions in Regulations 10 and 11 mean that the Regulations do not apply to certain communications that are restricted to trade/professional audiences or that meet the defined characteristics of reference and trade advertisements. However, those exceptions are not automatic; they depend on the factual circumstances (audience access, content limitations, and format).
Why Is This Legislation Important?
For practitioners, the Regulations are important because they create a clear compliance framework for pharmaceutical marketing in Singapore. The permit requirement is a gatekeeping mechanism: it forces regulatory review before promotional content reaches the public or relevant audiences. This reduces the risk of unapproved claims and helps ensure that promotional materials align with approved product information and regulatory expectations.
From an enforcement perspective, the Regulations are notable for (i) the licensing authority’s broad discretion to refuse, suspend, or revoke permits without giving reasons; (ii) the intermediary duty imposed on printers and publishers to verify permit status; and (iii) the offence provisions covering key compliance failures—particularly advertising without a permit, failure to display permit numbers, and unauthorised alterations after approval. These features mean that compliance failures can arise not only from the advertiser’s conduct but also from production and publishing workflows.
Practically, the Regulations require a disciplined internal process: regulatory approval tracking, version control for creative materials, amendment workflows for changes, and permit number placement. They also require careful contracting with agencies and publishers to ensure that intermediaries understand their verification duties and that marketing teams do not treat permit approval as a one-time event. Finally, the transfer rule is critical during corporate restructurings and brand ownership changes.
Related Legislation
- Medicines Act (Chapter 176): In particular, sections 52 and 74 (authorising the Regulations), and section 51 (which is referenced in the definition of “medical advertisement”).
Source Documents
This article provides an overview of the Medicines (Medical Advertisements) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.